Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Partial Oral Therapy for Osteomyelitis and Endocarditis. Reply

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Long-Term Outcomes of Partial Oral Treatment of Endocarditis

    Research output: Contribution to journalLetterResearch

  5. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prostate Artery Embolization for Lower Urinary Tract Symptoms in Men Unfit for Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. 5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Matthew R Smith
  • Fred Saad
  • Simon Chowdhury
  • Stéphane Oudard
  • Boris A Hadaschik
  • Julie N Graff
  • David Olmos
  • Paul N Mainwaring
  • Ji Youl Lee
  • Hiroji Uemura
  • Angela Lopez-Gitlitz
  • Géralyn C Trudel
  • Byron M Espina
  • Youyi Shu
  • Youn C Park
  • Wayne R Rackoff
  • Margaret K Yu
  • Eric J Small
  • SPARTAN Investigators
  • Klaus Brasso (Member of study group)
View graph of relations

BACKGROUND: Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis.

METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo. All the patients continued to receive androgen-deprivation therapy. The primary end point was metastasis-free survival, which was defined as the time from randomization to the first detection of distant metastasis on imaging or death.

RESULTS: A total of 1207 men underwent randomization (806 to the apalutamide group and 401 to the placebo group). In the planned primary analysis, which was performed after 378 events had occurred, median metastasis-free survival was 40.5 months in the apalutamide group as compared with 16.2 months in the placebo group (hazard ratio for metastasis or death, 0.28; 95% confidence interval [CI], 0.23 to 0.35; P<0.001). Time to symptomatic progression was significantly longer with apalutamide than with placebo (hazard ratio, 0.45; 95% CI, 0.32 to 0.63; P<0.001). The rate of adverse events leading to discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo group. The following adverse events occurred at a higher rate with apalutamide than with placebo: rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%).

CONCLUSIONS: Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN ClinicalTrials.gov number, NCT01946204 .).

Original languageEnglish
JournalThe New England journal of medicine
Volume378
Issue number15
Pages (from-to)1408-1418
Number of pages11
ISSN0028-4793
DOIs
Publication statusPublished - 12 Apr 2018

    Research areas

  • Adenocarcinoma, Aged, Aged, 80 and over, Androgen Antagonists, Disease Progression, Disease-Free Survival, Double-Blind Method, Exanthema, Humans, Male, Middle Aged, Neoplasm Metastasis, Proportional Hazards Models, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant, Thiohydantoins, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

ID: 53667802